Clinical Trial Update: A Study of Ixekizumab (LY2439821) in Participants Aged ≥18 Years With Moderate-to-Severe Plaque or Active Psoriatic Arthritis in India [Phase 4]

View source ↗

Summary

A Phase 4 study evaluating ixekizumab for adults with plaque psoriasis or psoriatic arthritis in India has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis
• Psoriatic Arthritis

Drugs mentioned

• TALTZ (IXEKIZUMAB)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Plaque Psoriasis, Psoriatic Arthritis | Phase 4 | Status: COMPLETED | Results posted: 2025-08-22